Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access March 27, 2009

Characteristics of Pseudomonas aeruginosa isolates from intensive care unit

  • Burcin Ozer EMAIL logo , Muserref Tatman-Otkun , Dilek Memis and Metin Otkun
From the journal Open Medicine


The study looked at the antimicrobial resistance patterns, serotypes, molecular types, metallo beta-lactamase, and chromosomal betalactamase enzymes of P. aeruginosa strains isolated from the patients and the staffs of the intensive care unit. P. aeruginosa isolates from the patients as nosocomial pathogens and from the staffs were evaluated for their susceptibilities to the antimicrobials by the disk diffusion and E-test methods. Metallo beta-lactamase enzymes were investigated by E-test, the inducibility of β - lactamase enzymes were detected by the disk antagonism test. Serotyping was performed by slide agglutination method. The P. aeruginosa isolates were typed by pulsed field gel electrophoresis. Twenty-five P. aeruginosa strains from the patients and three from the staffs were isolated. Fifteen P. aeruginosa, eleven of which composed of MDR bacteria, were found in serogroup E, 7 strains in G, 4 strains in B, and 1 strain in serogroup A. In all 12 bacteria in the MDR and serogroup E, metallo beta-lactamase enzyme was found to be positive. And in other 15 strains, except the bacterium which could not be serotyped, chromosomal beta-lactamase was found to be positive. The result of the molecular typing showed PFGE A pattern. In conclusion, a pattern in PFGE which included bacteria from MDR and serogroup E, G which was observed in the P. aeruginosa strains which was isolated from the staff’s hands and from the 5 patients, and PFGE F pattern were found to be observed the most. Finally, the two different clonal strains were found to be established in the intensive care.

[1] Kiska D.L., Gilligan P.H., Pseudomonas, In: Muray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed., ASM Pres, Washington, 2003, 1970–1980 Search in Google Scholar

[2] Pollack M., Pseudomonas aeruginosa, In: Mandell GL, Bennett JE, Dolin R (Eds), Principles and Practice of Infectious Diseases. 4th ed., Churchill Livingstone, New York, 1995, 1980–2003 Search in Google Scholar

[3] Hancock R.E.W., Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria, Clin. Infect. Dis., 1998, 27 (Suppl), 93–99 in Google Scholar

[4] Gaynes R.P., Horan T.C., Surveillance of nosocomial infections, In: Mayhall CG (ed), Hospital Epidemiology and Infection Control.1st ed. Lippincott Willams and Wilkins, Philadelphia, 1996, 1017–1037 Search in Google Scholar

[5] Strausbaugh L.J., Sewell D.L., Tjoelker R.C., Heitzman T., Webster T., Ward T. et al., Comparison of three methods for recovery of yeasts from hands of health-care workers, J. Clin. Microbiol., 1996, 34, 471–473 10.1128/jcm.34.2.471-473.1996Search in Google Scholar

[6] Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests, CLSI document M2-A9, (2006) Search in Google Scholar

[7] Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Susceptibility Testing, CLSI document M100-S16 (2006) Search in Google Scholar

[8] Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F., Surveillance for antimicrobial susceptibility among clinical iosalates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2002, Antimicrob. Agents. Chemother., 2003, 47, 1681–1688 in Google Scholar

[9] Akata F., Otkun M., Teker B., Karabay O., Öğütlü A., Tuğrul M. et al., Frequencies of extended spectrum and chromosomal beta-lactamases in nosocomial gram-negative bacteria, Turkish Journal of Infection, 1997, 11, 256–259 Search in Google Scholar

[10] Goto S., Tsuji A., Oguri T., Kobayashi I., Nishida M., Yabuuchi E., Present situation of serotyping of Pseudomonas aeruginosa in Japan and correlation among three kinds of commercially available serotyping kits, J. Infect. Chemother., 1999, 5: 201–205 in Google Scholar

[11] Hernàndez J., Ferrús M.A., Hernàndez M., Owen R.J., Arbitrary primed PCR fingerprinting and serotyping of clinical Pseudomonas aeruginosa strains, FEMS Immun. Med. Microbiol., 1997, 17, 37–47 in Google Scholar

[12] Speijer H., Savelkoul P.H.M., Bonten M.J., Stobberingh E.E., Tjhie J.H.T., Application of different genotyping methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit, J. Clin. Microbiol., 1999, 37, 3654–3661 10.1128/JCM.37.11.3654-3661.1999Search in Google Scholar PubMed PubMed Central

[13] Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al., Interpreting Chromosomal DNA restriction patterns produced by Pulsed-Field Gel Electrophoresis: Criteria for bacterial strain typing, J. Clin. Microbiol., 1995, 33, 2233–2239 10.1128/jcm.33.9.2233-2239.1995Search in Google Scholar PubMed PubMed Central

[14] Henwood C.J., Livermore D.M., James D., Warner M. and the Pseudomonas study group, Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disk susceptibility test, J. Antimicrob. Chemother., 2001, 47, 789–799 in Google Scholar PubMed

[15] Swenson J.M., Hindler J.A., Peterson R.L., Antimicrobial agents and susceptibility testing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (Eds.), Manual of Clinical Microbiology. 8th ed. ASM Pres, Washington, 2003, 1178–1195 Search in Google Scholar

[16] Hall L.M.C., Lıvermore D., Gur D., Akova M., Akalın H.E., OXA-11, an extended-spectrum variant of OXA-10 (PSE-2), beta-lactamase from Pseudomonas aeruginosa, Antimicrob. Agents. Chemother., 1993, 37, 1637–1644 10.1128/AAC.37.8.1637Search in Google Scholar PubMed PubMed Central

[17] Walsh T.R., Toleman M.A., Poirel L., and Nordmann P., Metallo-Lactamases: the quiet before the storm? Clin. Microbiol. Rev., 2005, 18, 306–325 in Google Scholar PubMed PubMed Central

[18] Pournaras S., Maniati M., Petinaki E., Tzouvelekis S., Tsakris A., Legakis N.J. et al., Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4, J. Antimicrob. Chemother., 2003, 51, 1409–1414 in Google Scholar PubMed

[19] Vahaboglu H., Coskunkan F., Tansel O., Oztürk R., Sahin N., Koksal I. et al., Clinical importance of extended-spectrum beta-lactamase (PER-1 type)- producing Acinetobacter spp, and Pseudomonas aeruginosa strains, J. Med. Microbiol., 2001, 50, 642–645 10.1099/0022-1317-50-7-642Search in Google Scholar PubMed

[20] Lee K., Lee W.G., Uh Y., Ha G.Y., Cho J., Chong Y. et al., VIM and IMP-type metallo-beta-lactamaseproducing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals, Emerg. Infect. Dis., 2003, 9, 868–871 10.3201/eid0907.030012Search in Google Scholar

[21] Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R., Characterization of Pseudomonas aeruginosa isolates: occurance rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999, Clin. Infect. Dis., 2001, 32(Suppl 2), 146–155 in Google Scholar PubMed

[22] Shawar R.M., Macleod D.L., Garber R.L., Burns J.L., Stapp J.R., Clausen C.R. et al., Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, Antimicrob. Agents. Chemother., 1999, 43, 2877–2880 10.1128/AAC.43.12.2877Search in Google Scholar PubMed PubMed Central

[23] Wolter D.J., Smith-Moland E., Goering R.V., Hanson N.D., Lister P.D., Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital, Diag. Microbiol. Infec. Dis., 2004, 50, 43–50 in Google Scholar PubMed

[24] The International Pseudomonas aeruginosa Typing Study Group, A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis, J. Infect. Dis., 1994, 169, 134–142 10.1093/infdis/169.1.134Search in Google Scholar PubMed

[25] Tassios P.T., Gennimata V., Spaliara-Kalogeropoulou L., Kairis D., Koutsia C., Vatopoulos A.C. et al., Multiresistant Pseudomonas aeruginosa serogroup O11 outbreak in an intensive care unit, Clin. Microbiol. Infect., 1997, 3, 621–628 in Google Scholar PubMed

[26] Vale T.A., Gaston M.A., Pitt T.L., Subdivision of seroypes of Pseudomonas aeruginosa with monoclonal antibodies, J. Clin. Microbiol., 1988, 26, 1779–1782 10.1128/jcm.26.9.1779-1782.1988Search in Google Scholar PubMed PubMed Central

[27] Wu Y.L., Scott E.M., Po A.L.W., Tariq V.N., Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa, J. Antimicrob. Chemother., 1999, 44, 389–392 in Google Scholar PubMed

Published Online: 2009-3-27
Published in Print: 2009-6-1

© 2009 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 22.9.2023 from
Scroll to top button